These 5 tiny pests are creating big trouble for Indiana's environment
Some of the creepy-crawlies currently wreaking havoc on North American ecosystems have been in the United States for over a century, lurking out of sight. But others, like spotted lanternflies, are newer threats, and they're sweeping through Midwestern forests, fields and gardens with a fury.
In Indiana, some tree species have almost disappeared, vineyards are under threat and even urban gardeners are starting to see the health of their soil decline. Without natural predators, the pests are difficult to stop.
But it is possible to slow them down.
Scientists are quarantining infected forests, disrupting mating seasons and encouraging Hoosiers to learn how the creatures spread. Here's what you need to know about how five tiny pests are causing chaos in Indiana.
At first glance, an Asian jumping worm looks like any other slimy earthworm — they're slender, squishy, and probably squirming around in your garden beds.
But while most worms burrow deep into soil and poop out nutrients across the layers, Asian jumping worms stay close to the surface. Their castings, which look like used coffee grounds, is easily washed away by rainfall, and it's almost impossible to grow native plants, fruits or veggies in the low-nutrient dirt left behind.
The worms were brought to North America from eastern Asia over 100 years ago, but they've only recently become a major threat. Over the last decade, their populations exploded and began to spread rapidly across the Midwest. Now, Asian jumping worms have been reported across multiple cities and counties in Indiana, including Indianapolis and Bloomington.
'We're finding them kind of everywhere,' said Robert Bruner, an entomologist at Purdue University. 'People are sitting up and paying attention a lot now because their damage to the soil structure is really hard to fix.'
Stopping their spread is tricky, too. Bruner theorizes the worms and their eggs are being moved through contaminated soil, mulch and compost. His advice to gardeners: Stop sharing soil with your neighbors, leave new bags of fresh dirt to dry in the sun for a few days, which can kill worm eggs, and report any sightings of Asian jumping worms you find.
Ash trees used to line the streets of Indiana cities by the tens of thousands. Their huge canopies and leafy cover provided ample shade for Hoosiers far and wide. But now, most of these native trees are dead.
The tiny emerald ash borer is to blame, according to entomologists. The bright green wood beetles hail from Eastern Asia, and were first found in Indiana in 2004. They've since spread to every county in the state.
Emerald ash borers can kill a healthy ash within six years of first contact. After burrowing just underneath the bark, the beetles feast on tree tissue, which eventually disrupts an ash's ability to internally transport water and nutrients.
Despite killing most of their primary food source, emerald ash borers persist. The beetles survive in pockets across Indiana and neighboring states, feeding on the remaining ash living in backyards and forest groves.
'Emerald ash borer is a constant concern because there are still ash trees and people are still trying to preserve them,' said Bruner. He thinks the beetles have become a permanent part of the Indiana landscape.
Because dying ash trees can crash to the ground and endanger their surroundings, city officials and residents have removed dead and dying trees by the thousands. But some ash trees in parks and backyards have been preserved through recurring pesticide applications, a process that can sometimes save Hoosier homeowners money in the long run compared to the hefty cost of tree removal and replacement.
Spongy moths are the one of the most dangerous defoliators in the United States, meaning they can and will chew through as much foliage as they find. In 2021, the moths defoliated over nine million acres of forest across the country according to Purdue University.
An amateur entomologist brought spongy moth specimens to Boston from Europe in the late 1860s — the moths escaped, obviously — and the creatures have been chewing their way through New England and further west ever since.
But it isn't exactly the fuzzy, winged insect that is destroying forests. Rather, it's the larval stage of the moth's life cycle posing the threat: Caterpillars need to eat.
As they prepare to metamorphose, spongy moth caterpillars devour the leaf tissue from over 300 species of trees and shrubs: preferably oaks, but tamarack, white birch, pine and spruce, too.
Usually, trees can survive their first defoliation. But when their leaves are shredded up and eaten away year after year, trees quickly lose their ability to fend off disease and store energy over the winter, leading to death.
In Indiana, the spongy moth outlook is 'pretty bad,' according to Bruner. Roughly three quarters of Indiana's 4.4 million acres of forested land is at risk, according to the Indiana Department of Natural Resources (DNR).
The moths pose such a serious threat to Indiana's ecosystems that the DNR puts counties with large infestations into quarantine to prevent further spread. In some areas, the DNR is even spraying pheromones to confuse and disrupt mating between male and female moths, said Bruner.
Right now, the moths are largely sequestered to northern Indiana, but past sightings further south, like in the Hoosier National Forest, have entomologists on high alert.
Armed with piercing-sucking mouthparts and a penchant for hitchhiking, invasive spotted lanternflies found their way from the East Coast to Indiana by 2021. Every year, the bugs travel a little further into the state, jeopardizing forests, vineyards and orchards.
The creatures aren't technically flies. Rather they're planthoppers, which are more closely related to cicadas and aphids. And they're destructive.
By piercing into a plant's vascular tissue, spotted lanternflies suck up sap to get nutrients. Then, they excrete oodles of honeydew — a sugary, watery mess — over everything nearby, which attracts other pests and allows sooty mold to grow.
Spotted lanternflies can also destroy agricultural crops. In Indiana, scientists are worried about the vineyards strewn across the state. When thousands of spotted lanternflies swarm feed on grapevines, they can weaken the plants, reduce yield and kill them off entirely. They also attack black walnut and maple trees, which could impact the local maple syrup and timber industries, said Bruner.
The planthopper's path of spread across the United States has closely followed railways, and Bruner expects to see them spread even further south this year. Hoosiers can report spotted lanternfly sightings to the DNR by submitting information through the agency's online portal.
Asian longhorn beetles aren't a current threat to Indiana's ecosystems, but they're still keeping some entomologists up at night.
In the late 1990s, the beetles were found in Indianapolis and Porter County, according to previous reporting from IndyStar, and the threat was immediately eradicated, said Bruner.
But Asian longhorn beetles still exist in Ohio forests, albeit quarantined, and Bruner is encouraging Hoosiers to stay on high alert in case the beetle finds its way back to Indiana.
'They're one of the nastiest ones,' he said. 'If you see one, it means it's already too late.'
Asian longhorn beetles bore deep into tree trunks and gouge out large holes, creating chambers inside trees where young beetles feast and grow. They have a slight preference for maple trees but are happy to munch through most hardwoods, like elms, willows, birches and sycamores. As they emerge from trees, they leave behind small, perfectly circular holes — about the size of a No. 2 pencil.
Dying trees are left carved up and hollowed out, lacking access to internal water or nutrients.
"Trees can't survive that level of damage," said Bruner. 'Typically, you have to eradicate all the trees within that area just to guarantee they don't spread.'
The DNR encourages residents not to move firewood, which can easily spread pests like the Asian longhorn beetle, and report potential sightings to (866) 663-9684.
IndyStar's environmental reporting project is made possible through the generous support of the nonprofit Nina Mason Pulliam Charitable Trust.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
an hour ago
- Business Wire
From Seattle to Chiba: Okayama University Taps AGC Biologics' Global Pathway for New Therapeutic
SEATTLE & CHIBA, Japan--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, today announced a new service agreement with Okayama University, a prominent national university in Japan. This project will leverage AGC Biologics' global network, with the mammalian cell line development capabilities in Seattle, USA, and cGMP mammalian manufacturing facility in Chiba, Japan, working together to advance a new therapeutic program for the university. Under the agreement, AGC Biologics will perform cell line development with its proprietary CHEF1™ expression platform in Seattle. CHEF1's track record includes the production of more than 55 different molecules and the development of five commercial products brought to market. The program will then be transferred to the company's facility in Chiba for process development for clinical trials in 2026. The collaboration between its Asian and U.S. sites highlights AGC Biologics' ability to offer research institutions a seamless, global pathway from early-stage development to clinical manufacturing. 'This project is a perfect example of our winning global blend, combining the world-class cell line development excellence in Seattle with the most-advanced cGMP-compliant mammalian cell culture manufacturing capabilities available in Japan,' said Susumu Zen-in, General Manager of AGC Biologics' Chiba facility. 'By providing a high level of global standard expertise and an emphasis on flexibility, we're able to effectively serve prestigious academic institutions like Okayama University working to bring vital new medicines to patients.' Okayama University selected AGC Biologics for its integrated global network and its unique position in Japan. The Chiba facility offers mammalian cell culture-based services to serve the needs of customers from Japan and the surrounding regions. This partnership underscores AGC Biologics' commitment to supporting academic and research institutions by providing the technical creativity and specialized services needed to solve complex challenges and advance important new therapies. To learn more about AGC Biologics' global network of services, visit About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit


CBS News
3 hours ago
- CBS News
Astronomers capture birth of new solar system around a sun-like baby star
Astronomers have, for the first time, discovered the moment when planets started to form around a sun-like baby star, scientists reported Wednesday. The specks of planet-forming material are emerging around HOPS-315, a protostar or baby star located 1,300 light-years away from us. One light year is approximately 5.88 trillion miles. While astronomers have seen discs of gas and dust around protostars before, they've never before identified a new planetary system at such an early stage. Minerals in the system around HOPS-315 are just starting to form. "We're seeing a system that looks like what our Solar System looked like when it was just beginning to form," study co-author Merel van 't Hoff, a professor at Purdue University, said in a news release from the European Southern Observatory (ESO). The observatory paired up with NASA's Webb Space Telescope to identify the minerals forming the new solar system. Researchers turned to data from our own solar system to determine that these minerals show the start of a new system. In Earth's solar system, the first solid materials to form can now be found inside ancient meteorites. Those ancient meteorites contain a mineral called silicon monoxide, which only forms at extremely high temperatures, like those near a young star. Scientists were able to identify the formation of silicon monoxide around HOPS-315, which they said tells them they've caught the development of a solar system at an early stage. "This is the first time this early stage of planet-building has ever been observed outside our own Solar System," the Planetary Society wrote in a social media post about the discovery. The discovery marks "the birth of the seeds of the planets," study co-author Edwin Bergin, a professor at the University of Michigan, told CBS News. The silicate-mineral rich material around HOPS-315 will make planets after another million years or so. "So we are watching the beginnings of the construction of planets," Bergin said. With the discovery, Bergin said researchers now know what to look for to find other budding systems. ESO's Alma telescope network in Chile captured an image of the still-forming planetary system around HOPS-315. In orange, the image shows the distribution of carbon monoxide blowing away from HOPS-315. Blue shows a narrow jet of silicon monoxide, which is also beaming away from the baby star. Astronomers hope it can help them learn more about the dawn of our solar system. "This system is one of the best that we know to actually probe some of the processes that happened in our Solar System," van 't Hoff said in a news release. HOPS-315 is much younger than the Sun; it's about 100,000 years old, Bergin said. "So we get a glimpse of the system in its infancy," Bergin said in an email. "Given that the Sun is 4.6 Billion years old this is a baby star that is still gaining mass and getting bigger."


Business Wire
7 hours ago
- Business Wire
Nanochon Announces Health Canada Approval for First in Human Investigation
WASHINGTON--(BUSINESS WIRE)--Nanochon, a Washington, DC and Baltimore, MD-based orthopedic device biotech company developing an implant for treating articular cartilage defects in the knee, is thrilled to announce that it was granted Health Canada Approval for their first in human clinical trial. The trial will be led by Principal Investigator, Dr. Fathi Abuzgaya, who will collaborate with Sports Medicine Specialists, Drs. Joel Lobo, Kajeandra Ravichandiran and Marcin Kowalczuk as Sub-Investigators, at the Durham Bone & Joint Specialists (DBJS), located in Ontario, Canada. Dr. Fathi Abuzgaya is an orthopedic surgeon by training and an esteemed researcher with a track record over the last 25 years, leading +600 clinical trials in all phases and therapeutic areas. 'Our team is delighted that we are the first center to start enrolling participants for the Chondrograft™ study, which represents a novel, minimally invasive treatment for patients with loss of or damaged knee cartilage,' Dr. Abuzgaya commented. 'DBJS is a multidisciplinary musculoskeletal center providing non-operative and operative treatments with accessibility to a variety of sub-specialties. Our study site with dedicated researchers enables greater, more efficient patient recruitment for clinical research and we are privileged to support Nanochon.' The Nanochon Chondrograft™ System is being evaluated in a prospective, 10 patient, early feasibility study for use in knee cartilage restoration in eligible patients between 22 and 60 years of age having femoral condyle and /or trochlea articular cartilage lesions who have failed conservative therapy, in addition to meeting other criteria. The study is designed to assess the safety and performance of Chondrograft™, and procedural goals include regrowth of the cartilage-bone matrix, improvement in knee function and pain, and delayed need for arthroplasty. 'Achieving Health Canada approval allows us to gain the clinical data needed to take a giant step forward towards design and execution of a large pivotal North American study,' said Ben Holmes, CEO of Nanochon. 'We have the utmost confidence in Dr. Abuzgaya and his clinical team at DBJS to help us recruit the right patients and execute the trial protocol that we have so carefully designed.' While the first in human trial will take place in Canada, this represents just the first step towards a larger clinical program. 'Thousands of patients with chondral defects, that may evolve to osteoarthritis, live with a reduced quality of life. We are looking forward to the potential for a new treatment option and are excited to begin the Chondrograft™ study at DBJS,' states Dr. Joel Lobo. 'The results of this study could open up a new surgical option, that is minimally invasive to address this unmet clinical need.' Throughout the clinical trial design and regulatory approval process, Nanochon was supported by HN Clinical Consulting (Missouri). "Improving the lives of young adults and athletes by providing a solution to restore knee cartilage and hopefully help patients avoid costly knee replacement is a crucial therapy needed in the orthopedic world," said Heather Neill, Founder and Principal. "We appreciate Health Canada's thought-provoking questions throughout their review that helped us put forward the strongest application possible, which ultimately led to our approval.' HN Clinical Consulting will continue to support the full life cycle of Chondrograft™. About HN Clinical Consulting HN Clinical Consulting, LLC, brings a strategic focus to each project, keeping the goal of commercialization in sight. Building strong relationships with all stakeholders and maintaining a clinical strategic goal of project-oriented success to support long term Sponsor strategy/exit is key to development of clinical programs. The objective set is to stay ahead by planning for podium presence, publication, and reimbursement while designing the Clinical Investigational Plan. About Nanochon Nanochon is a biotech and medical device company focused on developing innovative orthopedic solutions. Chondrograft™ is a minimally-invasive 3D printed implant that has allowed for immediate weight-bearing and motion in pre-clinical studies. The implant is based on research from the Tissue Engineering and Nanotechnology lab at the George Washington University, and is designed to integrate with healthy tissue over time, for maximum stability and benefit to the patient. Nanochon has the potential to deliver more successful and longer-lasting recovery for patients than current standard of care. Our mission is to develop a new approach to treat cartilage defects so that the hundreds of thousands of young, active patients with joint damage can return to their lifestyles without undergoing costly and invasive short-term fixes.